Growth Metrics

OmniAb (OABI) EBITDA Margin (2022 - 2026)

OmniAb (OABI) reported EBITDA Margin of 54.27% for Q1 2026, up 39937.0% year-over-year from N/an in Q1 2025, and up 71.17% on a QoQ basis from 188.23% in Q4 2025.

OmniAb (OABI) has 5 years of EBITDA Margin data on file, last reported at 54.27% in Q1 2026.

  • Quarterly EBITDA Margin rose 39937.0% year-over-year to 54.27% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 200.26% (up 6444.0% YoY) and the FY2025 annual result came in at 369.49%, down 8719.0% from the prior year.
  • EBITDA Margin rose to 54.27% in Q1 2026 per OABI's latest filing, from 188.23% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 19.32% in Q4 2022 and bottomed at 810.18% in Q3 2025.
  • The 5-year median for EBITDA Margin is 212.84% (2023), against an average of 267.5%.
  • The widest annual swing landed in 2024, when EBITDA Margin plunged 55728 bps; it then soared 39937 bps in 2026.
  • Tracing OABI's EBITDA Margin over 5 years: stood at 19.32% in 2022, then plunged by 1598 bps to 289.38% in 2023, then surged by 49 bps to 146.98% in 2024, then fell by 28 bps to 188.23% in 2025, then surged by 71 bps to 54.27% in 2026.
  • Per Business Quant, the three latest OABI EBITDA Margin figures stand at 54.27% (Q1 2026), 188.23% (Q4 2025), and 810.18% (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 38.10%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 18.35%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 17.24%
10 OmniAb 334.72 Mn 291.75 Mn 14.41 Mn -54.27%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -54.27%
Dec 31, 2025 -188.23%
Sep 30, 2025 -810.18%
Jun 30, 2025 -416.19%
Mar 31, 2025 -453.64%
Dec 31, 2024 -146.98%
Sep 30, 2024 -473.73%
Jun 30, 2024 -214.14%
Mar 31, 2024 -593.34%
Dec 31, 2023 -289.38%
Sep 30, 2023 -287.35%
Jun 30, 2023 -212.84%
Mar 31, 2023 -36.07%
Dec 31, 2022 19.32%
Sep 30, 2022 -182.29%
Jun 30, 2022 -142.74%
Mar 31, 2022 -65.44%